Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. In addition to these issues, further barriers to drug access remain in the UK and US.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. In addition to these issues, further barriers to drug access remain in the UK and US.

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98

Pharmaceutical Technology

MAY 3, 2023

In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu. In 2017, FDA announced the Drug Competition Action Plan (DCAP) to allow consumers to get access to medicines.

Generic Medicine 98

Generic Medicine Drug Development Communication Diabetes 98

Pharmaceutical Technology

JANUARY 26, 2023

Patients with conditions with limited treatment options could one day be cured by these breakthrough therapeutics, with treatments for everything from cancers, Parkinson’s and Alzheimer’s to strokes, spinal cord injuries and diabetes. It is very promising what the future will bring.”

Communication 52

Communication Diabetes Drug Development 52